{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:42:35Z","timestamp":1793727755147,"version":"4.6.1"},"reference-count":34,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T00:00:00Z","timestamp":1645574400000},"content-version":"unspecified","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Bristol Myers Squibb"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2022,1,14]]},"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>CheckMate 920 (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02982954\">NCT02982954<\/jats:ext-link>) is a multicohort, phase 3b\/4 clinical trial of nivolumab plus ipilimumab treatment in predominantly US community-based patients with previously untreated advanced renal cell carcinoma (RCC) and clinical features mostly excluded from phase 3 trials. We report safety and efficacy results from the advanced non-clear cell RCC (nccRCC) cohort of CheckMate 920.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients with previously untreated advanced\/metastatic nccRCC, Karnofsky performance status \u226570%, and any International Metastatic Renal Cell Carcinoma Database Consortium risk received up to four doses of nivolumab 3\u2009mg\/kg plus ipilimumab 1\u2009mg\/kg every 3 weeks followed by nivolumab 480\u2009mg every 4 weeks for \u22642 years or until disease progression\/unacceptable toxicity. The primary endpoint was incidence of grade \u22653 immune-mediated adverse events (AEs) within 100 days of last dose of study drug. Key secondary endpoints included objective response rate (ORR), progression-free survival (PFS; both investigator-assessed), time to response (TTR), and duration of response (DOR), all using RECIST V.1.1. Overall survival (OS) was exploratory.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Fifty-two patients with nccRCC (unclassified histology, 42.3%; papillary, 34.6%; chromophobe, 13.5%; translocation-associated, 3.8%; collecting duct, 3.8%; renal medullary, 1.9%) received treatment. With 24.1 months minimum study follow-up, median duration of therapy (range) was 3.5 (0.0\u201325.8) months for nivolumab and 2.1 (0.0\u20133.9) months for ipilimumab. Median (range) number of doses received was 4.5 (1\u201328) for nivolumab and 4.0 (1\u20134) for ipilimumab. Grade 3\u20134 immune-mediated AEs were diarrhea\/colitis (7.7%), rash (5.8%), nephritis and renal dysfunction (3.8%), hepatitis (1.9%), adrenal insufficiency (1.9%), and hypophysitis (1.9%). No grade 5 immune-mediated AEs occurred. ORR (n=46) was 19.6% (95% CI 9.4 to 33.9). Two patients achieved complete response (papillary, n=1; unclassified, n=1), seven achieved partial response (papillary, n=4; unclassified, n=3), and 17 had stable disease. Median TTR was 2.8 (range 2.1\u201314.8) months. Median DOR was not reached (range 0.0+\u221227.8+); eight of nine responders remain without reported progression. Median PFS (n=52) was 3.7 (95% CI 2.7 to 4.6) months. Median OS (n=52) was 21.2 (95% CI 16.6 to not estimable) months.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Nivolumab plus ipilimumab for previously untreated advanced nccRCC showed no new safety signals and encouraging antitumor activity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02982954\">NCT02982954<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2021-003844","type":"journal-article","created":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T11:55:27Z","timestamp":1645703727000},"page":"e003844","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":127,"title":["Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b\/4 CheckMate 920 trial"],"prefix":"10.1136","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct02982954","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02982954","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02982954","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03075423","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0399-0965","authenticated-orcid":false,"given":"Scott S","family":"Tykodi","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, University of Washington, Seattle, Washington, USA"},{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucio N","family":"Gordan","sequence":"additional","affiliation":[{"name":"Florida Cancer Specialists, Gainesville, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S","family":"Alter","sequence":"additional","affiliation":[{"name":"John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Arrowsmith","sequence":"additional","affiliation":[{"name":"Sarah Cannon Research Institute\/Tennessee Oncology, PLLC, Chattanooga, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R","family":"Harrison","sequence":"additional","affiliation":[{"name":"Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivor","family":"Percent","sequence":"additional","affiliation":[{"name":"Florida Cancer Specialists, Port Charlotte, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Singal","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Van Veldhuizen","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Rochester Medical Center, Rochester, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0836-8542","authenticated-orcid":false,"given":"Daniel J","family":"George","sequence":"additional","affiliation":[{"name":"Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hutson","sequence":"additional","affiliation":[{"name":"Texas A&M University College of Medicine, Bryan, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, Bristol Myers Squibb, Princeton, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"Zoco","sequence":"additional","affiliation":[{"name":"Syneos Health, Braine l\u2019Alleud, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L","family":"Johansen","sequence":"additional","affiliation":[{"name":"US Medical Immunology & Fibrosis, Bristol Myers Squibb, Princeton, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash","family":"Rezazadeh Kalebasty","sequence":"additional","affiliation":[{"name":"Norton Cancer Institute, Norton Healthcare, Louisville, Kentucky, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,2,24]]},"reference":[{"key":"2025100304210214000_10.2.e003844.1","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/bju.12950","article-title":"Renal cell cancer histological subtype distribution differs by race and sex","volume":"117","author":"Lipworth","year":"2016","journal-title":"BJU Int"},{"key":"2025100304210214000_10.2.e003844.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2009.12.035"},{"key":"2025100304210214000_10.2.e003844.3","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20000801)89:3<604::AID-CNCR16>3.0.CO;2-Q"},{"key":"2025100304210214000_10.2.e003844.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.02.029"},{"key":"2025100304210214000_10.2.e003844.5","doi-asserted-by":"publisher","DOI":"10.1159\/000495366"},{"key":"2025100304210214000_10.2.e003844.6","article-title":"Evolving treatment paradigm in metastatic non clear cell renal cell carcinoma","volume":"23","author":"Gulati","year":"2020","journal-title":"Cancer Treat Res Commun"},{"key":"2025100304210214000_10.2.e003844.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.05.010"},{"key":"2025100304210214000_10.2.e003844.8","unstructured":"National Comprehensive Cancer Network . Kidney cancer version 3, 2022. Available: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/kidney.pdf [Accessed 5 Nov 2021]."},{"key":"2025100304210214000_10.2.e003844.9","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28151"},{"key":"2025100304210214000_10.2.e003844.10","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.eururo.2021.03.015","article-title":"A single-arm, multicenter, phase 2 study of lenvatinib plus everolimus in patients with advanced non-clear cell renal cell carcinoma","volume":"80","author":"Hutson","year":"2021","journal-title":"Eur Urol"},{"key":"2025100304210214000_10.2.e003844.11","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.clgc.2020.05.006","article-title":"Safety and efficacy of nivolumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase IIIb\/IV CheckMate 374 study","volume":"18","author":"Vogelzang","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"2025100304210214000_10.2.e003844.12","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0319-9"},{"key":"2025100304210214000_10.2.e003844.13","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1200\/JCO.20.02365","article-title":"Open-label, single-arm, phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced non-clear cell renal cell carcinoma","volume":"39","author":"McDermott","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025100304210214000_10.2.e003844.14","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1200\/JCO.19.01882","article-title":"Results of a multicenter phase II study of atezolizumab and bevacizumab for patients with metastatic renal cell carcinoma with variant histology and\/or sarcomatoid features","volume":"38","author":"McGregor","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025100304210214000_10.2.e003844.15","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.7_suppl.545","article-title":"A phase II study investigating the safety and efficacy of savolitinib and durvalumab in metastatic papillary renal cancer (CALYPSO)","volume":"37","author":"Powles","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025100304210214000_10.2.e003844.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126"},{"key":"2025100304210214000_10.2.e003844.17","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30413-9"},{"key":"2025100304210214000_10.2.e003844.18","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-001079"},{"key":"2025100304210214000_10.2.e003844.19","unstructured":"OPDIVO (nivolumab) [package insert]. Bristol Myers Squibb, Princeton, NJ 2021."},{"key":"2025100304210214000_10.2.e003844.20","unstructured":"European Medicines Agency . OPDIVO, summary of product characteristics. Available: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/opdivo-epar-product-information_en.pdf [Accessed 27 Jul 2021]."},{"key":"2025100304210214000_10.2.e003844.21","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0475"},{"key":"2025100304210214000_10.2.e003844.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2019.11.012"},{"key":"2025100304210214000_10.2.e003844.23","article-title":"Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920","author":"Emamekhoo","year":"2021","journal-title":"Cancer"},{"key":"2025100304210214000_10.2.e003844.24","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/26.4.404"},{"key":"2025100304210214000_10.2.e003844.25","doi-asserted-by":"publisher","DOI":"10.2307\/2530286"},{"key":"2025100304210214000_10.2.e003844.26","doi-asserted-by":"publisher","DOI":"10.2307\/2281868"},{"key":"2025100304210214000_10.2.e003844.27","doi-asserted-by":"crossref","first-page":"v621","DOI":"10.1093\/annonc\/mdx440.029","article-title":"CheckMate 214: efficacy and safety of nivolumab + ipilimumab (N+I) V sunitinib (S) for treatment-na\u00efve advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups","volume":"28","author":"Escudier","year":"2017","journal-title":"Annals of Oncology"},{"key":"2025100304210214000_10.2.e003844.28","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12020408","article-title":"Outcomes associated with first-line anti-PD-1\/ PD-L1 agents vs. sunitinib in patients with sarcomatoid renal cell carcinoma: a systematic review and meta-analysis","volume":"12","author":"Buonerba","year":"2020","journal-title":"Cancers"},{"key":"2025100304210214000_10.2.e003844.29","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00515-X"},{"key":"2025100304210214000_10.2.e003844.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.10.049"},{"key":"2025100304210214000_10.2.e003844.31","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3233\/KCA-180045","article-title":"Real-world outcome of 173 metastatic non-clear cell renal cell carcinoma (nccRCC) cases: the experience of the center group for genitourinary tumors","volume":"3","author":"Mart\u00edn","year":"2019","journal-title":"Kidney Cancer"},{"key":"2025100304210214000_10.2.e003844.32","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0372"},{"key":"2025100304210214000_10.2.e003844.33","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.7_suppl.547","article-title":"Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab + ipilimumab (N+I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC)","volume":"37","author":"Tannir","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025100304210214000_10.2.e003844.34","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0140-6736(21)00152-5","article-title":"A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial","volume":"397","author":"Pal","year":"2021","journal-title":"Lancet"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2021-003844","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T11:21:10Z","timestamp":1759490470000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2021-003844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":34,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2,24]]},"published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.1136\/jitc-2021-003844"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2021-003844","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2]]}}}